ATE435650T1 - 2,5-disubstituierte phenylmethanonderivative als glycintransporter-1-inhibitoren (glyt-1) zur behandlung von neurologischen und neuropsychiatrischen störungen - Google Patents
2,5-disubstituierte phenylmethanonderivative als glycintransporter-1-inhibitoren (glyt-1) zur behandlung von neurologischen und neuropsychiatrischen störungenInfo
- Publication number
- ATE435650T1 ATE435650T1 AT06700397T AT06700397T ATE435650T1 AT E435650 T1 ATE435650 T1 AT E435650T1 AT 06700397 T AT06700397 T AT 06700397T AT 06700397 T AT06700397 T AT 06700397T AT E435650 T1 ATE435650 T1 AT E435650T1
- Authority
- AT
- Austria
- Prior art keywords
- glyt
- treatment
- inhibitors
- disubstituted
- neurological
- Prior art date
Links
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 title abstract 3
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 2,5-DISUBSTITUTED PHENYLMETHANONE Chemical class 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05100280 | 2005-01-18 | ||
| PCT/EP2006/000127 WO2006077026A1 (en) | 2005-01-18 | 2006-01-10 | 2, 5-disubstituted phenyl methanone derivatives as glycine transporter 1 (glyt-i) inhibitors for the treatment of neurological and neuropsychiatry disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE435650T1 true ATE435650T1 (de) | 2009-07-15 |
Family
ID=35985447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06700397T ATE435650T1 (de) | 2005-01-18 | 2006-01-10 | 2,5-disubstituierte phenylmethanonderivative als glycintransporter-1-inhibitoren (glyt-1) zur behandlung von neurologischen und neuropsychiatrischen störungen |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7790763B2 (de) |
| EP (1) | EP1843767B1 (de) |
| JP (1) | JP2008527016A (de) |
| KR (1) | KR100935256B1 (de) |
| CN (1) | CN101141959B (de) |
| AT (1) | ATE435650T1 (de) |
| AU (1) | AU2006207650B2 (de) |
| BR (1) | BRPI0606730A2 (de) |
| CA (1) | CA2601326A1 (de) |
| DE (1) | DE602006007682D1 (de) |
| ES (1) | ES2326833T3 (de) |
| IL (1) | IL184439A (de) |
| MX (1) | MX2007008616A (de) |
| WO (1) | WO2006077026A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2406085T3 (es) * | 2006-06-22 | 2013-06-05 | F. Hoffmann-La Roche Ag | Derivados de fenil-metanona sustituida y su empleo como inhibidores de receptores de GlyT1 y GlyT2 |
| EP2202223B1 (de) | 2007-10-18 | 2017-01-25 | Takeda Pharmaceutical Company Limited | Heterocyclische verbindung als blut-rbp4 senkende agent |
| EP3215500A1 (de) | 2014-11-05 | 2017-09-13 | Dart NeuroScience (Cayman) Ltd. | Substituierte azetidinylverbindungen als glyt1-inhibitoren |
| WO2025198588A1 (en) * | 2024-03-20 | 2025-09-25 | Bridgene Biosciences, Inc. | Preparation of compound and crystalline forms thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2423847A1 (de) | 1973-05-28 | 1975-01-02 | Ciba Geigy Ag | Neue sulfamoylbenzoesaeureamide |
| DE2611705A1 (de) | 1976-03-18 | 1977-09-22 | Josef Dipl Chem Dr Rer N Klosa | N-5-(nitrofurfuryliden-)-1-amino- hydantoin enthaltende kristalloesungsmittel |
| IT1176613B (it) | 1984-08-14 | 1987-08-18 | Ravizza Spa | Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione |
| US5393771A (en) | 1993-05-12 | 1995-02-28 | Brisol-Myers Squibb Company | 4-substituted benzopyran and related compounds |
| US6001854A (en) * | 1996-05-31 | 1999-12-14 | Allelix Neuroscience Inc. | Pharmaceutical for treating of neurological and neuropsychiatric disorders |
| WO1997045423A1 (en) * | 1996-05-31 | 1997-12-04 | Trophix Neuroscience Inc. | Pharmaceutical for treating of neurological and neuropsychiatric disorders |
| PL342818A1 (en) | 1998-03-06 | 2001-07-02 | Janssen Pharmaceutica Nv | Glycin transport inhibitors |
| CA2322164A1 (en) * | 1998-03-06 | 1999-09-10 | Ludo Edmond Josephine Kennis | Glycine transport inhibitors |
| EP1296950A2 (de) * | 2000-04-20 | 2003-04-02 | NPS Allelix Corp. | Aminopiperidine zur verwendung als glyt-1-inhibitoren |
| DOP2001000189A (es) * | 2000-06-30 | 2002-03-30 | Pfizer Prod Inc | Benzofenonas y sulfonas como inhibidores de la captación de glicina |
| GB0021419D0 (en) | 2000-08-31 | 2000-10-18 | Oxford Glycosciences Uk Ltd | Compounds |
| JP2005502623A (ja) | 2001-07-02 | 2005-01-27 | ノボ ノルディスク アクティーゼルスカブ | 置換ピペラジンおよびジアゼパン |
| WO2003035602A1 (en) | 2001-10-25 | 2003-05-01 | Sankyo Company, Limited | Lipid modulators |
| US20060052597A1 (en) | 2002-10-22 | 2006-03-09 | Best Desmond J | Aryloxyalkylamine derivatives as h3 receptor ligands |
| SE0302116D0 (sv) * | 2003-07-21 | 2003-07-21 | Astrazeneca Ab | Novel compounds |
| AU2004263306B2 (en) | 2003-08-11 | 2010-04-22 | F. Hoffmann-La Roche Ag | Piperazine with or-substituted phenyl group and their use as GLYT1 inhibitors |
| DK1663232T3 (da) | 2003-09-09 | 2008-02-04 | Hoffmann La Roche | Benzimidazolderivater som human chymase-inhibitorer |
| JP4563387B2 (ja) | 2003-09-09 | 2010-10-13 | エフ．ホフマン−ラ ロシュ アーゲー | 精神病の処置のためのグリシン取り込み阻害剤としての１−ベンゾイル−ピペラジン誘導体 |
| GB0329362D0 (en) * | 2003-12-18 | 2004-01-21 | Glaxo Group Ltd | Compounds |
| EP1745018A1 (de) * | 2004-04-29 | 2007-01-24 | Merck & Co., Inc. | Inhibitoren des azetidinglycintransporters |
| ES2406085T3 (es) * | 2006-06-22 | 2013-06-05 | F. Hoffmann-La Roche Ag | Derivados de fenil-metanona sustituida y su empleo como inhibidores de receptores de GlyT1 y GlyT2 |
-
2006
- 2006-01-10 JP JP2007551582A patent/JP2008527016A/ja active Pending
- 2006-01-10 DE DE602006007682T patent/DE602006007682D1/de not_active Expired - Lifetime
- 2006-01-10 KR KR1020077018714A patent/KR100935256B1/ko not_active Expired - Fee Related
- 2006-01-10 MX MX2007008616A patent/MX2007008616A/es active IP Right Grant
- 2006-01-10 EP EP06700397A patent/EP1843767B1/de not_active Expired - Lifetime
- 2006-01-10 ES ES06700397T patent/ES2326833T3/es not_active Expired - Lifetime
- 2006-01-10 AU AU2006207650A patent/AU2006207650B2/en not_active Ceased
- 2006-01-10 CA CA002601326A patent/CA2601326A1/en not_active Abandoned
- 2006-01-10 WO PCT/EP2006/000127 patent/WO2006077026A1/en not_active Ceased
- 2006-01-10 CN CN2006800085770A patent/CN101141959B/zh not_active Expired - Fee Related
- 2006-01-10 BR BRPI0606730-1A patent/BRPI0606730A2/pt not_active IP Right Cessation
- 2006-01-10 AT AT06700397T patent/ATE435650T1/de active
- 2006-01-17 US US11/332,999 patent/US7790763B2/en not_active Expired - Fee Related
-
2007
- 2007-07-05 IL IL184439A patent/IL184439A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006077026A1 (en) | 2006-07-27 |
| US20060160788A1 (en) | 2006-07-20 |
| BRPI0606730A2 (pt) | 2009-07-14 |
| CN101141959B (zh) | 2010-12-15 |
| DE602006007682D1 (de) | 2009-08-20 |
| MX2007008616A (es) | 2007-09-11 |
| IL184439A (en) | 2011-11-30 |
| AU2006207650A1 (en) | 2006-07-27 |
| JP2008527016A (ja) | 2008-07-24 |
| AU2006207650B2 (en) | 2011-01-27 |
| EP1843767A1 (de) | 2007-10-17 |
| EP1843767B1 (de) | 2009-07-08 |
| KR20070094971A (ko) | 2007-09-27 |
| US7790763B2 (en) | 2010-09-07 |
| CA2601326A1 (en) | 2006-07-27 |
| IL184439A0 (en) | 2007-10-31 |
| ES2326833T3 (es) | 2009-10-20 |
| KR100935256B1 (ko) | 2010-01-06 |
| CN101141959A (zh) | 2008-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
| NO20071967L (no) | Imidazo-benzodiazepinderivater | |
| EA200901373A1 (ru) | Аминогетероциклические соединения | |
| ATE493407T1 (de) | 3-(heteroaryloxy)-2-alkyl-1- azabicycloalkylderivate als alpha.7-nachr- liganden zur behandlung von zns-erkrankungen | |
| NO20064726L (no) | Imidazolforbindelser for behandling av neurodegenerative forstyrrelser | |
| BRPI0406762A (pt) | Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça | |
| ATE438632T1 (de) | Aryl-4-ethinylisoxazolderivate | |
| MY148145A (en) | Methods of synthesis and/or purification of diaminophenothiazinium compounds | |
| ATE402935T1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen | |
| MEP45308A (en) | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
| MXPA04003007A (es) | Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades. | |
| ATE472327T1 (de) | Ä4-(heteroaryl)piperazin-1-ylü-(2,5-substituier e phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
| DE50310609D1 (de) | Cyclische amide | |
| IL190867A0 (en) | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives | |
| IL186777A0 (en) | (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor | |
| ATE414703T1 (de) | Isoxazolderivate als inverse gaba a alpha5 agonisten | |
| ATE486058T1 (de) | Prolinamidderivate als nk3-antagonisten | |
| ATE512147T1 (de) | Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer | |
| NO20073330L (no) | Sulfanylsubstituerte fenylmetanoner som glycintransportor 1 (glyt-1) inhibitorer for behandling av nevrologiske og nevropsykiatriske forstyrrelser | |
| WO2006055434A3 (en) | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| IL184439A0 (en) | 2,5-disubstituted phenyl methanone derivatives as glycine transporter 1 | |
| ATE469891T1 (de) | Sauerstoffhaltige heterocyclen als glycintransporterinhibierende verbindungen | |
| DE602006014022D1 (de) | 5-substituierte indol-2-carbonsäureamidderivate | |
| EA200701758A1 (ru) | Замещённые арильные производные 1,4-пиразина | |
| ATE378339T1 (de) | Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1843767 Country of ref document: EP |